ABBV - Idera says AbbVie has discontinued enrollment in its study for tilsotolimod combo

Updating the progress of clinical trials for the company’s Toll-like receptor 9 agonist, tilsotolimod, Idera Pharmaceuticals (NASDAQ:IDRA) said that its partner AbbVie (NYSE:ABBV) has discontinued further patient enrollment in an early-stage study for a combination therapy involving the drug. The Phase 1b trial was designed to assess ABBV-368 plus tilsotolimod and other therapeutic combinations in recurrent/metastatic head and neck squamous cell carcinoma. The decision was not related to safety concerns. The treatments and follow-up are currently ongoing in the study, Idera (IDRA) added. Meanwhile, in its ILLUMINATE-206 study for tilsotolimod, out of eight evaluable patients, one patient had experienced Stable Disease (SD) with disease control for more than six months. Other evaluable patients had witnessed progressive disease (PD) according to the company. In the ongoing trial, tilsotolimod is being studied with ipilimumab and nivolumab among previously treated patients with a specific form of colorectal cancer (immunotherapy-naïve micro-satellite stable colorectal cancer).

For further details see:

Idera says AbbVie has discontinued enrollment in its study for tilsotolimod combo